(616 Kb) -

The study highlighted a few differences between "real-world" patients and those in trials:

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies . (616 KB)

The search for a "616 KB" article points directly to a significant medical study titled The study highlighted a few differences between "real-world"

: For those who stopped the medication, the median time until they did so was only 7 months . (616 KB)

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group.

: Finding ways to help patients manage side effects so they can stay on the therapy longer.